Your browser doesn't support javascript.
loading
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.
Holmes, Frankie Ann; Levin, Maren K; Cao, Ying; Balasubramanian, Sohail; Ross, Jeffrey S; Krekow, Lea; McIntyre, Kristi; Osborne, Cynthia; Espina, Virginia; Liotta, Lance; O'Shaughnessy, Joyce.
Afiliación
  • Holmes FA; Texas Oncology, Houston, TX.
  • Levin MK; US Oncology McKesson Specialty Health, The Woodlands, TX.
  • Cao Y; Baylor University Medical Center, Dallas, TX.
  • Balasubramanian S; Valley Medical Oncology Consultants, Pleasanton, CA.
  • Ross JS; Celsius Therapeutics, Cambridge, MA.
  • Krekow L; Upstate Medical University, Syracuse, NY.
  • McIntyre K; Foundation Medicine, Cambridge, MA.
  • Osborne C; US Oncology McKesson Specialty Health, The Woodlands, TX.
  • Espina V; Texas Oncology, Bedford, TX.
  • Liotta L; US Oncology McKesson Specialty Health, The Woodlands, TX.
  • O'Shaughnessy J; Texas Oncology, Dallas, TX.
JCO Precis Oncol ; 3: 1-26, 2019 Dec.
Article en En | MEDLINE | ID: mdl-35100698
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: JCO Precis Oncol Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: JCO Precis Oncol Año: 2019 Tipo del documento: Article